4D pharma today announced it registered with the SEC to list on the Nasdaq under the symbol ‘LBPS’ following its proposed merger with Longevity Acquisition. The deal is expected to close in Q1 2021, pending shareholder approval. Shareholders earlier this week voted to grant the SPAC an extension until May 2021 to close a deal. Longevity has filed a preliminary proxy on the proposed combination. Read more.
Related Posts
DHC Acquisition Prices Upsized $300M IPO
DHC Acquisition intends to focus on the technology, aerospace/defense, enterprise software, automotive supply chain, consumer and E-commerce sectors.
Wejo Group Limited Merging with TKB Critical Technologies 1 in Deal Expected to Raise $100M
The structure of the transaction seeks to limit TKB stockholder redemptions and maximize cash delivered to Wejo by providing TKB investors with an approximately 10% premium to the estimated cash in TKB’s trust in Wejo Holdings shares.
Frontier Investment Chops 20% Off Deal Ahead of $200M IPO
The new SPAC said it will focus on the technology, digital media, e-commerce, financial technology, or digital services sectors.
SportsTek Acquisition Signs Non-Binding LOI for Potential Deal with Metavisio
The proposed transaction is based on an enterprise value of Metavisio of $140 million to $160 million, pending due diligence.